Evaluation of antifungal combinations of nystatin-intralipid against Aspergillus terreus using checkerboard and disk diffusion methods

Journal de Mycologie Medicale

Volumn 25, Issue 1, 2015, Pages 63-70

  Semis, R ^a,b   Nahmias, M ^a   Lev, S ^a   Frenkel, M ^a   Segal, E ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antifungal combinations; Aspergillus terreus; Checkerboard assay; Disk diffussion assay; Nystatin Intralipid

Indexed keywords

CASPOFUNGIN; FLUCYTOSINE; INTRALIPID; NYSTATIN; NYSTATIN INTRALIPID; TERBINAFINE; UNCLASSIFIED DRUG; VORICONAZOLE; ANTIFUNGAL AGENT; DRUG COMBINATION; ECHINOCANDIN; EMULSION; NAPHTHALENE DERIVATIVE; PHOSPHOLIPID; SOYBEAN OIL; SOYBEAN OIL, PHOSPHOLIPID EMULSION;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS TERREUS; CHECKERBOARD ASSAY; DISK DIFFUSION; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL STRAIN; HYDROPHOBICITY; IN VITRO STUDY; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; ADMINISTRATION AND DOSAGE; ASPERGILLUS; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; EMULSION; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; PHARMACOLOGY; PROCEDURES;

ASPERGILLUS TERREUS;

ANTIFUNGAL AGENTS; ASPERGILLUS; DRUG COMBINATIONS; ECHINOCANDINS; EMULSIONS; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; NYSTATIN; PHOSPHOLIPIDS; SOYBEAN OIL; VORICONAZOLE;

EID: 84924519548     PISSN: 11565233     EISSN: 17730449     Source Type: Journal    
DOI: 10.1016/j.mycmed.2014.12.002     Document Type: Article

References (32)

1. Arikan S., Lozano-Chiu M., Paetznick V., Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
2. Banerjee D., Burkard L., Panepinto J.C. Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B. PLoS One 2014, 9:e87246.
3. Caillot D., Thieberbrecht R., Herbrecht R., de Botton S., Pigneux A., Bernard F., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740-2746.
4. Clinical, Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, Second Edition: Approved Standard M38-A2 2008, CLSI, Wayne, PA, USA.
5. de Pauw B. Antifungal therapy. Transplant Proc 2011, 43:2461-2462.
6. Gianni C. Update on antifungal therapy with terbinafine. G Ital Dermatol Venereol 2010, 145:415-424.
7. Hazen E.L., Brown R. Nystatin. Ann N Y Acad Sci 1960, 89:258-266.
8. Hope W., Natarajan P., Goodwin L. Invasive fungal infections. Clin Med 2013, 13:507-510.
9. Johnson E.M., Espinel-Ingroff A.V., Pfaller M.A. Susceptibility test methods: yeasts and filamentous fungi. Manual of Clinical Microbiology 2011, vol. 2:2020-2037. ASM, Washington DC. 10th ed.
10. Kurosawa M., Yonezumi M., Hashino S., Tanaka J., Nishio M., Kaneda M., et al. Epidemiology and treatment outcome of invasive fungal infections in patientswith hematological malignancies. Int J Hematol 2012, 96:748-757.
11. Lass-Florl C., Griff K., Mayr A., Petzer A., Gastl G., Bonatti H., et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005, 131:201-207.
12. Lewis R.E. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011, 86:805-817.
13. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., Ghannoum1 M.A. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005, 18:163-194.
14. Ng A.W., Wasan K.M., Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci 2003, 6:67-83.
15. Perfect J.R., DismukesWE, Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010, 50:291-322.
16. Pitman S.K., Drew R.H., Perfect J.R. Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations. Expert Opin Emerg Drugs 2011, 16:559-586.
17. Reed C., Bryant R., Ibrahim A.S., Edwards J., Filler S.G., Goldberg R., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364-371.
18. Larone D.H. The genus Aspergillus, in medically important fungi, a guide to identifican 2011, 281-293. ASM Press, Washington D.C, USA. 5th ed.
19. Sandovsky-Losica H., Shwartzman R., Lahat Y., Segal E. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B. J Antimicrob Chemother 2008, 62:635-637.
20. Scheven M., Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995, 39:1779-1783.
21. Semis R., Kagan S., Berdicevsky I., Polacheck I., Segal E. Mechanism of activity and toxicity of nystatin-intralipid. Med Mycol 2013, 51:422-431.
22. Semis R., Mendlovic S., Polacheck I., Segal E. Activity of an Intralipid formulation of nystatin in murine systemic candidiasis. Int J Antimicrob Agents 2011, 38:336-340.
23. Semis R., Nili S.S., Munitz A., Zaslavsky Z., Polacheck I., Segal E. Pharmacokinetics, tissue distribution and immunomodulatory effect of intralipid formulation of nystatin in mice. J Antimicrob Chemother 2012, 67:1716-1721.
24. Semis R., Polacheck I., Segal E. Nystatin-intralipid preparation: characterization and in vitro activity against yeasts and molds. Mycopathologia 2010, 169:333-341.
25. Shadkchan Y., Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother 1999, 44:787-790.
26. Shadkchan Y., Segal E. Treatment of experimental candidosis with amphotericin B-intralipid admixtures in immunocompromised mice. J Antimicrob Chemother 2001, 48:245-251.
27. Shadkhan Y., Segal E., Bor A., Gov Y., Rubin M., Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother 1997, 39:655-658.
28. Sionov E., Segal E. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures. Med Mycol 2004, 42:73-80.
29. Sionov E., Mendlovic S., Segal E. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. J Infect 2006, 53:131-139.
30. Sipsas N.V., Kontoyiannis D.P. Invasive fungal infections in patients with cancer in the Intensive Care Unit. Int J Antimicrob Agents 2012, 39:464-471.
31. Steinbach W.J., Benjamin D.K., Kontoyiannis D.P., Perfect J.R., Lutsar I., Marr K.A., et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004, 39:192-198.
32. Sugar A.M. Antifungal combination therapy: where we stand. Drug Resist Updat 1998, 1:89-92.